Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

We have read with interest the article by Reyes et al1. The article describes a network meta-analysis (NMA) of trials including patients with hemophilia A without inhibitors, assessing the relative efficacy of emicizumab versus factor VIII (FVIII) prophylaxis.